End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,055 KRW | -16.97% | -10.26% | -45.35% |
18/03 | Shaperon Enrolls its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel' | CI |
2022 | Shaperon Inc. has completed an IPO in the amount of KRW 13.735 billion. | CI |
Sales 2022 | 200Cr 14.64L 12Cr | Sales 2023 | 22Cr 2L 1.31Cr | Capitalization | 8.67TCr 6.35Cr 529.91Cr |
---|---|---|---|---|---|
Net income 2022 | -1.07TCr -78.13L -65Cr | Net income 2023 | -1.24TCr -90.79L -76Cr | EV / Sales 2022 | 64 x |
Net cash position 2022 | 3.16TCr 2.31Cr 192.91Cr | Net cash position 2023 | 1.95TCr 1.43Cr 119.37Cr | EV / Sales 2023 | 312 x |
P/E ratio 2022 |
-13.3
x | P/E ratio 2023 |
-6.96
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.35% |
1 day | -16.97% | ||
1 week | -10.26% | ||
Current month | -7.01% | ||
1 month | -1.20% | ||
3 months | -31.50% | ||
6 months | -38.29% | ||
Current year | -45.35% |
Managers | Title | Age | Since |
---|---|---|---|
Seung-Yong Sung
CEO | Chief Executive Officer | - | - |
Date | Price | Change | Volume |
---|---|---|---|
05/24/05 | 2,055 | -16.97% | 2,561,856 |
04/24/04 | 2,475 | +15.93% | 13,860,710 |
03/24/03 | 2,135 | -3.39% | 2,666,739 |
31/24/31 | 2,210 | -5.15% | 3,988,446 |
30/24/30 | 2,330 | +1.75% | 15,447,720 |
End-of-day quote Korea S.E., June 05, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-45.35% | 3.46Cr | |
+19.01% | 12TCr | |
+14.59% | 11TCr | |
-3.18% | 2.47TCr | |
+3.03% | 2.27TCr | |
-9.98% | 1.81TCr | |
-41.04% | 1.67TCr | |
-13.04% | 1.66TCr | |
+0.99% | 1.35TCr | |
+23.36% | 1.13TCr |
- Stock Market
- Equities
- A378800 Stock